HK Stock Market Move | BIOCYTOGEN-B (02315) increases by over 6% again, reaching a new high. The company has officially entered the Hong Kong Stock Connect. Institutions believe that the prospects for Biocytogen are broad.

BIOCYTOGEN-B (02315) rose by more than 6% in early trading, reaching a high of HK$37.28, setting a new record high for its listing. As of the time of writing, it is up by 5.99%, trading at HK$37.18 with a turnover of HK$78.79 million. On the news front, recently, the Shanghai Stock Exchange and the Shenzhen Stock Exchange announced that BioCytoGen has been included in the list of stocks eligible for trading through the Stock Connect program, effective from December 24, 2025. BioCytoGen stated that the successful inclusion in the Stock Connect program is another important milestone in the company's capital market development process, following the establishment of a dual A+H listing platform, marking a new phase in the company's accessibility to capital, market recognition, and long-term investment value. Galaxy Securities released a research report stating that BioCytoGen, with gene editing technology as its foundation, is expected to see a significant increase in performance as the company's major investment, the Thousand Mice Anti-Cancer Plan, enters the realization stage. The report points out that after the company's listing on the Science and Technology Innovation Board, with a dual capital layout of A+H shares, the liquidity of A shares is better; as a platform for primary listing, the Hong Kong stock market has been included in the Stock Connect program effective from December 24, 2025, with a significant discount in valuation and a relatively high safety margin.